Clinical trials: Hematopoietic Neoplasms
Lymphoma
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.
- Trial name
- NCT03200977
- Testing
- Non-Interventional
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Bristol-Myers Squibb
AML
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication…
- Trial name
- NCT02039726
- Testing
- Quizartinib, Salvage Chemotherapy
- Where
- 131 sites in United States, Australia and 17 more
- Volunteers
- 367 people
- Sponsor
- Daiichi Sankyo
Advanced Non-Hematologic Malignancies
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic…
- Trial name
- NCT01653158
- Testing
- CP-751,871, Docetaxel
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Pfizer
Multiple Myeloma
Exploratory Study on POL6326 in Stem Cell Mobilization
The purpose of this study is to determine whether POL6326 is safe and clinically active to mobilize hematopoietic stem cells followed by transplantation
- Trial name
- NCT01105403
- Testing
- POL6326
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Polyphor Ltd.
Multiple Myeloma
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by…
- Trial name
- CARTITUDE-5 (NCT04923893)
- Testing
- Bortezomib, Dexamethasone, Lenalidomide
- Where
- 136 sites in United States, Argentina and 24 more
- Volunteers
- 743 people
- Sponsor
- Janssen Research & Development, LLC
Hematologic Malignancies
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia
The purpose of this study is to determine if MultiStem® can safely be given to patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia after they have received hematopoietic stem cell transplantation.
- Trial name
- NCT00677859
- Testing
- MultiStem®
- Where
- 6 sites in United States, Belgium
- Volunteers
- 36 people
- Sponsor
- Healios K.K.
Viral Infection
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
The subjects eligible for this trial have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- ARMS (NCT01570283)
- Testing
- Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- AlloVir
Hodgkin Lymphoma, Non Hodgkin Lymphoma
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
High-dose chemotherapy followed by blood stem cell transplantation is administered to lymphoma patients with an intention to cure.
- Trial name
- E-CELERATE (NCT05181540)
- Testing
- AB-205
- Where
- 28 sites in United States
- Volunteers
- 130 people
- Sponsor
- Angiocrine Bioscience
Leukemia, Myelodysplastic Syndromes
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00064090
- Testing
- cytarabine, triapine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
CMV Retinitis
Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.
The goal of this exploratory clinical study is to evaluate the safety and efficacy of Cytomegalovirus-Specific T cells (LB-DTK-CMV) to treat patients diagnosed with antiviral-resistant and refractory cytomegalovirus retinitis.
- Trial name
- NCT07679412
- Testing
- LB-DTK-CMV
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- LucasBio
Leukemia, Leukemia, Myeloid
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type
- Trial name
- CYNK001AML01 (NCT04310592)
- Testing
- CYNK-001
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celularity Incorporated
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
This study aim is to assess, if treosulfan pharmacokinetics are influenced by declined renal function and by race/ethnicity of patients.
- Conditions
- Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- NCT05534620
- Testing
- Treosulfan, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- medac GmbH
Advanced Solid Malignancies
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed…
- Trial name
- NCT04521413
- Testing
- CFI-402411, Pembrolizumab
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 170 people
- Sponsor
- Treadwell Therapeutics, Inc
Adenovirus Infection, BK Virus Infection
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT05305040)
- Testing
- Posoleucel (ALVR105)
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 451 people
- Sponsor
- AlloVir
Multiple Myeloma, Non-hodgkin's Lymphoma
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
This Phase II study is to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 alone or in combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease.
- Conditions
- Multiple Myeloma, Non-hodgkin's Lymphoma, Hodgkin's Disease
- Trial name
- NCT01458288
- Testing
- TG-0054
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- GPCR Therapeutics, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
Study CR-AIR-006 is a part of the ATIR clinical development plan and will provide control data for patients treated with ATIR in clinical studies (e.g. study CR-AIR-007).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02188290
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 178 people
- Sponsor
- Kiadis Pharma
Leukemia
Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation
Efficacy study about donor derived CD19-target T cell to treat B-ALL post hematopoietic stem cell transplantation
- Trial name
- NCT04336501
- Testing
- IM19 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Neoplasm Metastasis, Neoplasm Recurrence
PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy
The objectives of this Phase I/II study are: 1. To find out the maximum tolerated dose (MTD) of PG2 in patients with advanced malignancy receiving chemotherapy and to define a "Study Dose" for Phase II. 2.
- Trial name
- NCT01696565
- Testing
- PG2
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- PhytoHealth Corporation
Hematopoietic Neoplasm
Phase 2 Study of SAR302503 in Patients With Myelofibrosis
Primary Objective: To evaluate the efficacy of daily oral doses of 300 mg, 400 mg, and 500 mg SAR302503 for the reduction of spleen volume as determined by magnetic resonance imaging (MRI).
- Trial name
- NCT01420770
- Testing
- SAR302503
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma
Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma
Primary Objective: To determine if non-Hodgkin Lymphoma (NHL) participants mobilized with granulocyte colony-stimulating factor (G-CSF) plus plerixafor 240 μg/kg are more likely to achieve a target number of greater than or equal…
- Trial name
- NCT02221492
- Testing
- plerixafor GZ316455, Filgrastim
- Where
- 12 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Genzyme, a Sanofi Company